Challenges in immunotherapy for colorectal cancer: Perspectives from the immune microenvironment

Xiaofang Ma; Tianyue Jiang; Jiameng Miao; Xianbin Kong

doi:10.36922/EJMO026050047

Eurasian Journal of Medicine and Oncology ›› 2026, Vol. 10 ›› Issue (3) :026050047 DOI: 10.36922/EJMO026050047

EDITORIAL

research-article

Challenges in immunotherapy for colorectal cancer: Perspectives from the immune microenvironment

Author information +

History +

PDF (402KB)

Cite this article

Download citation ▾

Xiaofang Ma, Tianyue Jiang, Jiameng Miao, Xianbin Kong. Challenges in immunotherapy for colorectal cancer: Perspectives from the immune microenvironment. Eurasian Journal of Medicine and Oncology, 2026, 10 (3) : 026050047 DOI:10.36922/EJMO026050047

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. doi: 10.3322/caac.21834

[2]	Lin X, Zong C, Zhang Z, Fang W, Xu P. Progresses in ers for cancer immunotherapy. MedComm. 23;4(5):e387. doi: 10.1002/mco2.387

[3]	Yang C, Guo S, Ye K, et al. A trispecific antibody engaging T cells with tumour and myeloid cells augments antitumour immunity. Nat Biomed Eng. Published online January 22, 2025. doi: 10.1038/s41551-025-01569-4

[4]	de Torres CS, Elias E, Vaghi C, et al. Exploring resistance to immune checkpoints inhibitors in mismatch repair-deficient or microsatellite-instable colorectal cancer. Cancer Treat Rev. 2026; 143:103089. doi: 10.1016/j.ctrv.2026.103089

[5]	Lenz HJ, Parikh A, Spigel DR, et al. Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: Phase 2 results from the CheckMate 9X8 randomized clinical trial. J Immunother Cancer. 2024; 12(3):e008409. doi: 10.1136/jitc-2023-008409

[6]	Fakih M, Raghav KPS, Chang DZ, et al. Regorafenib plus nivolumab in patients with mismatch repair- proficient/microsatellite stable metastatic colorectal cancer: A single-arm, open-label, multicentre phase 2 study. EClinicalMedicine. 2023; 58:101917. doi: 10.1016/j.eclinm.2023.101917